First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer
First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer is a paper indexed in ScholarIQ from OpenAlex.
How many citations does First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer have?
First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer has 70 citations in the OpenAlex counts ScholarIQ stores.
When was First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer published?
First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer has 2025 year in the ScholarIQ index.
What is the open-access status of First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer?
First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer has closed oa status in the ScholarIQ index.
What is the DOI of First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer?
The DOI for First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer is on the source record.
What is the PMID of First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer?
The PMID for First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer is on the source record.
What is the OpenAlex record for First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer?
The OpenAlex for First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer is on the source record.